LHW090
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 30, 2018
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
(clinicaltrials.gov)
- P2; N=84; Recruiting; Sponsor: Novartis Pharmaceuticals; N=40 ➔ 84
Enrollment change • Biosimilar • Chronic Kidney Disease • Renal Disease
September 18, 2018
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
(clinicaltrials.gov)
- P2; N=84; Active, not recruiting; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Active, not recruiting
Enrollment closed • Biosimilar • Chronic Kidney Disease • Renal Disease
1 to 2
Of
2
Go to page
1